معرفی
Prof. Dr. Regina Hofmann-Lehmann is a Professor at the Clinical Laboratory and Center for Clinical Studies (ZKS) within the Vetsuisse Faculty of the University of Zurich. Her research integrates molecular tools with clinical infectiology and laboratory medicine to address critical veterinary infectious disease challenges, primarily using feline models.
Her research program centers on retroviral pathogenesis (feline immunodeficiency virus and feline leukemia virus) and hemotropic Mycoplasma infections. Key investigations include host-virus interactions, provirus carrier dynamics, antiretroviral strategies targeting FeLV reservoirs, tumor marker development, and host-pathogen mechanisms in infectious anemia. The group maintains a specialized facility for specified pathogen-free cats under controlled conditions, enabling longitudinal studies of infection dynamics and treatment efficacy.
Analysis of 2023-2025 publications reveals dominant themes in feline infectious disease management, particularly feline infectious peritonitis (FIP) therapeutics using GS-441524, diagnostic test validation, and zoonotic disease surveillance. Research spans antiviral pharmacology, immunodiagnostics, hematopathology, and comparative oncology, demonstrating translational relevance to human medicine through shared disease mechanisms.
No scientific awards were documented in the provided sources.
Retroviral research is funded by the Swiss National Science Foundation. The group's infrastructure includes a dedicated pathogen-free cat facility supporting controlled infection studies. While specific student mentorship details are absent, the prolific publication output (over 50 articles since 2021) indicates active supervision of graduate researchers and technical staff in molecular virology and clinical diagnostics.
The laboratory operates within Zurich's Vetsuisse Faculty Clinical Laboratory and Center for Clinical Studies, leveraging advanced facilities for molecular pathogen characterization, host immune response analysis, and antiviral efficacy testing. Current projects focus on optimizing FIP treatment protocols, developing FeLV provirus eradication strategies, and characterizing novel hemotropic Mycoplasma species across mammalian hosts.
